Chugai Presents Results of Two Pivotal Phase III Studies for its Bispecific Antibody HEMLIBRA® at WFH 2018
(WorldNews Japan)

TOKYO, May 21, 2018 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) today announced that full results from the HAVEN 3 study (NCT02847637) and HAVEN 4 study (NCT03020160) evaluating Chugai`s hemophilia A treatment HEMLIBRA®[generic name: emicizumab (genetical recombination)] are being presented at the World Federation of Hemophilia 2018 World Congress held in Glasgow, Scotland from May 20 to 24. HAVEN 3 study is conducted in people with hemophilia A without inhibitors, and HAVEN 4 study is conducted in people with hemophilia A with or without inhibitors. Results from both studies will be presented as late-breaking abstracts. `The results from HAVEN 3 study demonstrate that HEMLIBRA, which...